AAAAAA

   
Results: 1-8 |
Results: 8
[F-18]FDOPA and [F-18]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease
Authors: Rinne, JO Nurmi, E Ruottinen, HM Bergman, J Eskola, O Solin, O
Citation: Jo. Rinne et al., [F-18]FDOPA and [F-18]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease, SYNAPSE, 40(3), 2001, pp. 193-200
Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging
Authors: Ruottinen, HM Niinivirta, M Bergman, J Oikonen, V Solin, O Eskola, O Eronen, E Sonninen, P Rinne, UK
Citation: Hm. Ruottinen et al., Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging, SYNAPSE, 40(1), 2001, pp. 19-26
Rate of progression in Parkinson's disease: A 6-[F-18]fluoro-L-dopa PET study
Authors: Nurmi, E Ruottinen, HM Bergman, J Haaparanta, M Solin, O Sonninen, P Rinne, JO
Citation: E. Nurmi et al., Rate of progression in Parkinson's disease: A 6-[F-18]fluoro-L-dopa PET study, MOVEMENT D, 16(4), 2001, pp. 608-615
Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [F-18] CFT
Authors: Nurmi, E Ruottinen, HM Kaasinen, V Bergman, J Haaparanta, M Solin, O Rinne, JO
Citation: E. Nurmi et al., Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [F-18] CFT, ANN NEUROL, 47(6), 2000, pp. 804-808
Upregulation of putaminal dopamine D-2 receptors in early Parkinson's disease: A comparative PET study with [C-11]raclopride and [C-11]N-methylspiperone
Authors: Kaasinen, V Ruottinen, HM Nagren, K Lehikoinen, P Oikonen, T Rinne, JO
Citation: V. Kaasinen et al., Upregulation of putaminal dopamine D-2 receptors in early Parkinson's disease: A comparative PET study with [C-11]raclopride and [C-11]N-methylspiperone, J NUCL MED, 41(1), 2000, pp. 65-70
An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome
Authors: Ruottinen, HM Partinen, M Hublin, C Bergman, J Haaparanta, M Solin, O Rinne, JO
Citation: Hm. Ruottinen et al., An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome, NEUROLOGY, 54(2), 2000, pp. 502-504
[C-11]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy - Correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology
Authors: Lamusuo, S Pitkanen, A Jutila, L Ylinen, A Partanen, K Kalviainen, R Ruottinen, HM Oikonen, V Nagren, K Lehikoinen, P Vapalahti, M Vainio, P Rinne, JO
Citation: S. Lamusuo et al., [C-11]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy - Correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology, NEUROLOGY, 54(12), 2000, pp. 2252-2260
[F-18]FDG-PET and whole-scalp MEG localization of epileptogenic cortex
Authors: Lamusuo, S Forss, N Ruottinen, HM Bergman, J Makela, JP Mervaala, E Solin, O Rinne, JK Ruotsalainen, U Ylinen, A Vapalahti, M Hari, R Rinne, JO
Citation: S. Lamusuo et al., [F-18]FDG-PET and whole-scalp MEG localization of epileptogenic cortex, EPILEPSIA, 40(7), 1999, pp. 921-930
Risultati: 1-8 |